The FDA approved the world's first CAR-T therapy on Wednesday, one month ahead of schedule, and only days after Gilead Sciences announced it’s buying CAR-T powerhouse Kite Pharma in a deal valued at $11.9 billion.

The FDA approved the world's first CAR-T therapy on Wednesday, one month ahead of schedule, and only days after Gilead Sciences announced it’s buying CAR-T powerhouse Kite Pharma in a deal valued at $11.9 billion.

The FDA approved the world's first CAR-T therapy on Wednesday, one month ahead of schedule, and only days after Gilead Sciences announced it’s buying CAR-T powerhouse Kite Pharma in a deal valued at&nbsp;$11.9 billion.&nbsp; &nbsp;

Healthcare: Gilead Sciences Couldn't Have Timed its Splash Into CAR-T Better

Healthcare, technology, energy, consumer goods, and more. Every day, Motley Fool analysts break down a specific industry and the stocks making headlines. Questions? Comments? Email us at IndustryFocus@fool.com.

Share Healthcare: Gilead Sciences Couldn't Have Timed its Splash Into CAR-T Better

Sign up to save your podcasts

Healthcare: Gilead Sciences Couldn't Have Timed its Splash Into CAR-T Better

Healthcare: Gilead Sciences Couldn't Have Timed its Splash Into CAR-T Better

More shows like Industry Focus

Motley Fool Money

Motley Fool Answers

Rule Breaker Investing

MarketFoolery